Crinetics Pharmaceuticals Shares Exciting Developments
In a significant announcement, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) revealed that it is granting equity awards under its 2021 Employment Inducement Incentive Award Plan. This initiative was aimed at attracting new talent, showcasing the company’s commitment to fostering growth and innovation in the pharmaceutical industry.
Details on Stock Option and RSU Awards
On a recent date, the Compensation Committee of Crinetics’ Board of Directors approved the issuance of non-qualified stock options and restricted stock unit (RSU) awards. Specifically, 74,000 shares were allocated for stock options and 48,850 RSUs were designated for 20 non-executive employees. These awards serve as a strategic move to entice individuals into joining Crinetics, marking a promising step toward expanding their workforce.
Structure of the Awards
The stock options come with an exercise price of $33.08 per share, aligning with the closing price of Crinetics’ stock on the Nasdaq Global Select Market. The vesting schedule for stock options is structured over four years, with the first 25% vesting after one year, followed by monthly installments thereafter. Similarly, the RSUs will also vest annually after an initial one-year period, promoting retention and motivating employees to contribute to Crinetics’ ongoing success.
About the 2021 Inducement Plan
This inducement plan is designed to reward those who are joining the company for the first time or returning after a break in their employment. Under Nasdaq Listing Rule 5635(c)(4), it offers a framework that exclusively facilitates granting equity awards to new hires, ensuring these individuals are incentivized from the outset.
Crinetics Pharmaceuticals: A Leader in Endocrine Therapeutics
Crinetics Pharmaceuticals is recognized for its innovative approach towards tackling endocrine diseases and related tumors. At the forefront of their development efforts is paltusotine, a groundbreaking daily oral medication intended to treat acromegaly and carcinoid syndrome. This candidate stands out as the first nonpeptide agonist targeting the somatostatin receptor type 2 (SST2), showcasing their dedication to pioneering treatments in this specialized area.
Contributions to Endocrine Health
The company is also advancing Atumelnant, which is under development for conditions such as congenital adrenal hyperplasia and Cushing’s syndrome. Crinetics is committed to producing small-molecule drugs that are designed for oral administration, coming from extensive in-house drug discovery initiatives.
Diverse Pipeline of Drug Candidates
In addition to these lead candidates, Crinetics is actively exploring treatments for a variety of endocrine disorders—including hyperparathyroidism, polycystic kidney disease, and Graves’ disease, which includes thyroid eye disease. Their research is also building pathways towards therapeutic solutions for diabetes, obesity, and oncology indications targeting G protein-coupled receptors (GPCRs).
Contact Information for Investors and Media
For inquiries, investors can reach out to Gayathri Diwakar, who leads Investor Relations at Crinetics Pharmaceuticals. Interested parties can connect with her via email or by phone at (858) 345-6340.
For media-related inquiries, Natalie Badillo, the Head of Corporate Communications, is available for contact at (858) 450-6464, ensuring that all communications regarding Crinetics are handled promptly and professionally.
Frequently Asked Questions
What is the purpose of the stock options and RSU awards granted by Crinetics?
The stock options and RSUs are granted to attract and retain new employees as an incentive to join Crinetics Pharmaceuticals.
How many shares are included in the stock options granted?
A total of 74,000 shares are included in the stock options granted to new hires.
What is the exercise price for the stock options?
The exercise price for the stock options is set at $33.08 per share.
What is the vesting schedule for the RSUs?
The RSUs vest over four years in equal annual installments starting after one year from the vesting commencement date.
What company does the announcement pertain to?
The announcement pertains to Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a leader in the development of therapeutics for endocrine diseases.
